Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) EBIT Margin (2020 - 2026)

Opus Genetics has reported EBIT Margin over the past 8 years, most recently at 665.92% for Q1 2026.

  • Quarterly EBIT Margin fell 43872.0% to 665.92% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 359.13% through Mar 2026, up 11187.0% year-over-year, with the annual reading at 271.9% for FY2025, 29282.0% up from the prior year.
  • EBIT Margin was 665.92% for Q1 2026 at Opus Genetics, down from 296.33% in the prior quarter.
  • Over five years, EBIT Margin peaked at 85.85% in Q4 2022 and troughed at 883.98% in Q4 2024.
  • The 5-year median for EBIT Margin is 302.67% (2025), against an average of 338.42%.
  • Year-over-year, EBIT Margin plummeted -60224bps in 2024 and then soared 58766bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 85.85% in 2022, then plummeted by -474bps to 321.05% in 2023, then crashed by -175bps to 883.98% in 2024, then soared by 66bps to 296.33% in 2025, then tumbled by -125bps to 665.92% in 2026.
  • Per Business Quant, the three most recent readings for IRD's EBIT Margin are 665.92% (Q1 2026), 296.33% (Q4 2025), and 269.93% (Q3 2025).